

Kim Jong Joseph  
Form 4  
August 25, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kim Jong Joseph

(Last) (First) (Middle)

C/O INOVIO  
PHARMACEUTICALS,  
INC., 11494 SORRENTO VALLEY  
ROAD, SUITE A

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
INOVIO PHARMACEUTICALS,  
INC. [INO]

3. Date of Earliest Transaction  
(Month/Day/Year)  
08/23/2011

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired (A)<br>or Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                |
|---------------------------------------|---|---|--------------------------------------|---|--|---|---|----------------|
| Common<br>Stock                       |   |   |                                      | (A)<br>or<br>(D)  | Price  |   |   |                |
|                                       |   |   |                                      |   | 11,870,722<br>(1)  | D   |   |                |
| Common<br>Stock                       |   |   |                                      |   | 23,900 (1)   | I   | By Spouse   |                |
| Common<br>Stock                       | 08/23/2011                              |   | P                                    | 20,000 A  | \$<br>0.6464   | 20,000 (1)  | I   | By Son:<br>JK1 |
| Common<br>Stock                       | 08/24/2011                              |   | P                                    | 15,000 A  | \$<br>0.6553   | 35,000 (1)  | I   | By Son:<br>JK1 |

# Edgar Filing: Kim Jong Joseph - Form 4

|              |            |   |        |   |          |                       |   |                 |
|--------------|------------|---|--------|---|----------|-----------------------|---|-----------------|
| Common Stock | 08/24/2011 | P | 35,000 | A | \$ 0.666 | 35,000 <sup>(1)</sup> | I | By Daughter: EK |
| Common Stock | 08/24/2011 | P | 26,659 | A | \$ 0.666 | 26,659 <sup>(1)</sup> | I | By Son: JK2     |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |

## Reporting Owners

| Reporting Owner Name / Address  | Director | 10% Owner | Officer                 | Other |
|---|----------|-----------|-------------------------|-------|
| Kim Jong Joseph<br>C/O INOVIO PHARMACEUTICALS, INC.<br>11494 SORRENTO VALLEY ROAD, SUITE A<br>SAN DIEGO, CA 92121 | X        | X         | Chief Executive Officer |       |

## Signatures

/s/ Jong Joseph Kim 08/24/2011

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This Form 4 reflects the purchase of an aggregate of 96,659 shares of common stock of Inovio Pharmaceuticals, Inc. in the name of

- (1) Joseph Kim's children. Column 5 of Table I now reflects the proper allocation between Dr. Kim's direct and indirect ownership of the shares listed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.